The maddening itch: An approach to chronic urticaria

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 1, 2014, Pages 1-5

  Viegas, L P ^a   Ferreira, M B ^a   Kaplan, A P ^b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

CU index; Fc RI; Omalizumab; Spontaneous chronic urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN; DIPHENHYDRAMINE; FC RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PREDNISONE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY;

AUTOIMMUNITY; CHRONIC URTICARIA; HISTAMINE RELEASE; HISTOLOGY; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; THYROID FUNCTION; VASODILATATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; CYCLOSPORINE; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRURITUS; URTICARIA;

EID: 84895886866     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Zuberbier T, Bindsley-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, Kapp A, Kozel MM, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):321-31.
2. Sabroe R, Greaves M. What is Urticaria? Anatomical, Physiological, and Histological Considerations and Classification. In: Kaplan A, Greaves M, editors. Urticaria and Angioedema. New York: Informa Healthcare; 2009. p. 1-14.
3. Hellgren L. The prevalence of urticaria in the total population. Acta Allergol. 1972;27(3):236-40.
4. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869-73.
5. Simons F, Simons K. Urticaria: Principles of Antihistamine Treatment. In: Kaplan A, Greaves M, editors. Urticaria and Angioedema. New York: Informa Healthcare; 2009. p. 341-64.
6. Viswanathan RK, Biagtan MJ, Mathur SK. The role of autoimmune testing in chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(5):337-41.
7. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869-73.
8. Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CE, Black AK, Stingl G, Greaves MW, Barr RM. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002;110(3):492-9.
9. Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, Black MM, Black AK, Greaves MW. Cutaneous inflammatory cell infiltration in chronic idiopathic urticaria: Comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol. 1999;103(3Pt1):484-93.
10. Kaplan A, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777-87.
11. Kikuchi Y, Kaplan AP. A role of C5a in augmenting IgGdependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol. 2002;109(1):114-8.
12. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001;107(6):1056-62.
13. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol. 1999;104(1):169-72.
14. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria-a clinical, immunological and histological evaluation. Br J Dermatol. 1986;114(5):583-90.
15. Khalaf A, Li W, Jinquan T. Current advances in the management of urticaria. Arch Immunol Ther Exp. 2008;56(2):103-14.
16. Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol. 1983;119(8):636-40.
17. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84(1):66-71.
18. Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clinic Rev Allerg Immunol. 2012 [Epub ahead of print].
19. Saini SS, Paterniti M, Vasagar K, Gibbons S, Sterba PM, Vonakis BM. Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2. Clin Immunol. 2009;132(3):342-8.
20. Vonakis BM, Vasagar K, Gibbons SP Jr, Gober L, Sterba PM, Chang H, Saini SS. Basophil FcεRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119(2):441-8.
21. Platzer MH, Grattan CE, Poulsen LK, Skov PS. Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. Allergy. 2005;60(9):1152-6.
22. Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol. 2006;154(5):813-9.
23. Biagtan MJ, Viswanathan RK, Evans MD, Mathur SK. Clinical utility of the Chronic Urticaria Index. J Allergy Clin Immunol. 2011;127(6):1626-7
24. Lapolla W, Desai N, English JC 3rd. Clinical utility of testing for autoimmunity in chronic idiopathic urticaria. J Am Acad Dermatol. 2012;66(3):e83-8.
25. Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy. 2010;65(11):1478-82.
26. Hollander SM, Joo SS, Wedner HJ. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol. 2011;107(6):523-28.
27. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, Schmid-Grendelmeier P, Skov PS, Grattan CE. EAACI task-force position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68(1):27-39.
28. Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol. 2003;28(2):123-7.
29. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175-9.
30. Powell RJ, Du Toit GL, Siddique N, Lech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM. BSACI guidelines for the management of chronic urticaria and angiooedema. Clin Exp Allergy. 2007;37(5):631-50.
31. Zuberbier T. Urticaria. Allergy. 2003;58(12):1224-34.
32. Kaplan AP. What to do with refractory urticaria patients. Curr Allergy Asthma Rep. 2011;11(3):1889-91.
33. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86(6Pt2):1014-8.
34. Breneman D. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother. 1996;30(10):1075-9.
35. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676-82.
36. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672-9.
37. Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009;123(3):713-7.
38. Kaplan AP. Treatment of Chronic Urticaria: Approaches other than Antihistamines. In: Kaplan A, Greaves M, editors. Urticaria and Angioedema. New York: Informa Healthcare; 2009. p. 365-72
39. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria. J Investig Allergol Clin Immunol. 2010;20(5):386-90.
40. Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black Am Greaves MW. Randomized doubleblind study of cyclosporin in chronic "idiopathic" urticaria. Br J Dermatol. 2000;143(2):365-72.
41. Toubi E, Blant A. Kessel A, Golan TD. Low-dose cyclosporine A in the treatment of severe chronic idiopathic urticaria. Allergy. 1997;52(3):312-6.
42. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004;114(3):465-74.
43. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo-controlled, doseranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-73.
44. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569-73.
45. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406-11.
46. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202-9.
47. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-35.
48. Kaplan, A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Juna P, Berger W, Maurer M, Rosen K. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-109